{"title":"Coronaviruses: A Scientist’s Race Against Time","authors":"Saloni Chaurasia","doi":"10.51627/pghr.2020.04.00007","DOIUrl":null,"url":null,"abstract":"As the clock ticks, more and more people are falling victim to COVID-19, and scientists are racing against time to find treatment and prevention strategies. But what’s stopping them? The answer comes from two primary problems. Firstly, coronaviruses (CoVs) are transmitted from person-to-person via respiratory droplets from an infected person’s coughs or sneezes, which makes them highly contagious (CDC, How COVID-19 Spreads, 2020). This can happen in minutes, and up to 25% of patients remain asymptomatic (Du, et al., 2020). This makes it difficult for healthcare workers and researchers to contain patients and establish contact tracing to isolate the infected population. Secondly, it is hard to target CoVs without damaging our cells. CoVs infect via spike protein, which binds to the ACE2 receptor located on the lung alveolar epithelial cells (Hoffmann, et al., 2020). Once they invade the cell, CoVs hijack the host cell’s mechanisms to replicate. Thus, it is hard to combat the virus without damaging the host cell. On the other hand, recent understanding of CoVs structure and mechanism of action enables the scientific world to create a cure or vaccine. The bad news is that these efforts will likely face the perennial hurdles of medical innovation and discovery, long timelines of clinical trials for drug repurposing, and vaccine development, sometimes fickle funding, and changing governmental priorities.","PeriodicalId":310759,"journal":{"name":"The Pre-Collegiate Global Health Review","volume":"32 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Pre-Collegiate Global Health Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51627/pghr.2020.04.00007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
As the clock ticks, more and more people are falling victim to COVID-19, and scientists are racing against time to find treatment and prevention strategies. But what’s stopping them? The answer comes from two primary problems. Firstly, coronaviruses (CoVs) are transmitted from person-to-person via respiratory droplets from an infected person’s coughs or sneezes, which makes them highly contagious (CDC, How COVID-19 Spreads, 2020). This can happen in minutes, and up to 25% of patients remain asymptomatic (Du, et al., 2020). This makes it difficult for healthcare workers and researchers to contain patients and establish contact tracing to isolate the infected population. Secondly, it is hard to target CoVs without damaging our cells. CoVs infect via spike protein, which binds to the ACE2 receptor located on the lung alveolar epithelial cells (Hoffmann, et al., 2020). Once they invade the cell, CoVs hijack the host cell’s mechanisms to replicate. Thus, it is hard to combat the virus without damaging the host cell. On the other hand, recent understanding of CoVs structure and mechanism of action enables the scientific world to create a cure or vaccine. The bad news is that these efforts will likely face the perennial hurdles of medical innovation and discovery, long timelines of clinical trials for drug repurposing, and vaccine development, sometimes fickle funding, and changing governmental priorities.
随着时间的流逝,越来越多的人成为COVID-19的受害者,科学家们正在争分夺秒地寻找治疗和预防策略。但是是什么阻止了他们呢?答案来自两个主要问题。首先,冠状病毒(cov)通过感染者咳嗽或打喷嚏产生的呼吸道飞沫在人与人之间传播,这使得它们具有高度传染性(疾病预防控制中心,2019年COVID-19如何传播)。这可能在几分钟内发生,高达25%的患者仍然无症状(Du, et al., 2020)。这使得卫生保健工作者和研究人员难以控制患者并建立接触者追踪以隔离受感染人群。其次,很难在不损害细胞的情况下靶向冠状病毒。冠状病毒通过刺突蛋白感染,刺突蛋白与肺泡上皮细胞上的ACE2受体结合(Hoffmann, et al., 2020)。一旦它们侵入细胞,冠状病毒就会劫持宿主细胞的机制进行复制。因此,很难在不破坏宿主细胞的情况下对抗病毒。另一方面,最近对冠状病毒结构和作用机制的了解使科学界能够开发出治疗方法或疫苗。坏消息是,这些努力可能会面临医疗创新和发现的长期障碍,药物重新用途的临床试验需要很长时间,疫苗开发,有时资金变化无常,以及政府优先事项的变化。